Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
12 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Regentis Biomaterials Ltd.’s names, not what it holds today.
Patents granted
12
12 utility, 1976 to Dec 31, 2025
Granted in 2025
1
in the last year the record reads
Applications published
17
since 2001, to Dec 31, 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'06'10'11'12'14'15'16'17'18'19'22'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
REGENTIS BIOMATERIALS LTD. its own name
IL, as the owner printed on each patent. 1 more under the same name are not counted (printed in US)
13 publishedREGENTIS BIOMATERIALS LTD. its own name
named as the applicant on its applications, in IL
4 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Nov 11, 2025 | 12,465,668 | Organic solvent free compositions comprising protein-polymer conjugates and uses thereof | Medical technology | REGENTIS BIOMATERIALS LTD. |
| Oct 8, 2019 | 10,434,215 | Compositions comprising a polymer-protein conjugate and an environmentally-responsive polymer and uses thereof | Medical technology | REGENTIS BIOMATERIALS LTD. |
| Feb 20, 2018 | 9,895,519 | Treatment of cavities in a human body | Medical technology | REGENTIS BIOMATERIALS LTD. |
| Jan 23, 2018 | 9,872,705 | Treatment of cavities in a human body | Medical technology | REGENTIS BIOMATERIALS LTD. |
| Jul 11, 2017 | 9,700,600 | Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same | Pharmaceuticals | REGENTIS BIOMATERIALS LTD. |
| Apr 18, 2017 | 9,624,259 | Compositions and methods for scaffold formation | Medical technology | REGENTIS BIOMATERIALS LTD. |
| Oct 25, 2016 | 9,474,830 | PEGylated fibrinogen precursor molecule | Pharmaceuticals | REGENTIS BIOMATERIALS LTD. |
| Sep 1, 2015 | 9,120,872 | Matrix composed of a naturally-occurring protein backbone cross linked by a synthetic polymer and methods of generating and using same | Pharmaceuticals | REGENTIS BIOMATERIALS LTD. |
| Oct 14, 2014 | 8,858,925 | Pegylated fibrinogen precursor molecule | Pharmaceuticals | REGENTIS BIOMATERIALS LTD. |
| Sep 30, 2014 | 8,846,020 | Scaffolds formed from polymer-protein conjugates, methods of generating same and uses thereof | Pharmaceuticals | REGENTIS BIOMATERIALS LTD. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Apr 7, 2022 | 2022/0105240 | ORGANIC SOLVENT FREE COMPOSITIONS COMPRISING PROTEIN-POLYMER CONJUGATES AND USES THEREOF | Medical technology | REGENTIS BIOMATERIALS LTD. · patent 12,465,668 granted from it |
| Mar 21, 2019 | 2019/0083642 | TREATMENTS UTILIZING A POLYMER-PROTEIN CONJUGATE | Pharmaceuticals | REGENTIS BIOMATERIALS LTD. |
| Dec 20, 2018 | 2018/0361021 | ORGANIC SOLVENT FREE COMPOSITIONS COMPRISING PROTEIN-POLYMER CONJUGATES AND USES THEREOF | Medical technology | REGENTIS BIOMATERIALS LTD. |
| Jun 29, 2017 | 2017/0182214 | COMPOSITIONS AND METHODS FOR SCAFFOLD FORMATION | Medical technology | REGENTIS BIOMATERIALS LTD. |
| Dec 29, 2016 | 2016/0375174 | PEGYLATED FIBRINOGEN PRECURSOR MOLECULE | Pharmaceuticals | REGENTIS BIOMATERIALS LTD. |
| Oct 13, 2016 | 2016/0296666 | COMPOSITIONS COMPRISING A POLYMER-PROTEIN CONJUGATE AND AN ENVIRONMENTALLY-RESPONSIVE POLYMER AND USES THEREOF | Medical technology | REGENTIS BIOMATERIALS LTD. · patent 10,434,215 granted from it |
| Dec 17, 2015 | 2015/0359856 | MATRIX COMPOSED OF A NATURALLY-OCCURRING PROTEIN BACKBONE CROSS LINKED BY A SYNTHETIC POLYMER AND METHODS OF GENERATING AND USING SAME | Pharmaceuticals | REGENTIS BIOMATERIALS LTD. · patent 9,700,600 granted from it |
| Jul 30, 2015 | 2015/0209562 | TREATMENT OF CAVITIES IN A HUMAN BODY | Medical technology | REGENTIS BIOMATERIALS LTD. · patent 9,872,705 granted from it |
| Apr 9, 2015 | 2015/0100041 | TREATMENT OF CAVITIES IN A HUMAN BODY | Medical technology | REGENTIS BIOMATERIALS LTD. · patent 9,895,519 granted from it |
| Jan 29, 2015 | 2015/0030580 | PEGYLATED FIBRINOGEN PRECURSOR MOLECULE | Pharmaceuticals | REGENTIS BIOMATERIALS LTD. · patent 9,474,830 granted from it |
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.